Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sagimet Biosciences Inc Series A (SGMT)

Sagimet Biosciences Inc Series A (SGMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

SGMT : 5.55 (-2.46%)
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

SGMT : 5.55 (-2.46%)
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

SGMT : 5.55 (-2.46%)
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

SGMT : 5.55 (-2.46%)
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024

SGMT : 5.55 (-2.46%)
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024

SGMT : 5.55 (-2.46%)
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

SGMT : 5.55 (-2.46%)
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug

Sagimet Biosciences’ SGMT stock rose 12.6% on Tuesday after it announced that the FDA has granted breakthrough therapy designation (“BTD”) to its lead pipeline candidate, denifanstat, for treating...

VKTX : 51.72 (-2.30%)
MDGL : 325.18 (-0.92%)
AKRO : 32.09 (-0.03%)
SGMT : 5.55 (-2.46%)
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

GALT : 2.85 (-1.38%)
GLMD : 2.82 (-1.53%)
VKTX : 51.72 (-2.30%)
ETNB : 9.57 (+6.45%)
IVA : 2.60 (-1.89%)
SGMT : 5.55 (-2.46%)
TERN : 6.16 (-1.28%)
NVO : 108.71 (+1.79%)
IQV : 201.78 (+0.47%)
MDGL : 325.18 (-0.92%)

Barchart Exclusives

Is Palantir Stock Set for a Drop?
While Palantir’s growth story is compelling, its valuation has become a topic of debate. The stock’s meteoric rise has priced in much of its future potential, as reflected by analysts’ average price targets. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar